Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax Inc (NQ: NVAX )

13.61 -0.81 (-5.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,522,083
Open 14.46
Bid (Size) 13.65 (1)
Ask (Size) 13.70 (6)
Prev. Close 14.42
Today's Range 13.18 - 14.70
52wk Range 3.532 - 23.86
Shares Outstanding 74,484,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much $1000 Invested In Novavax 5 Years Ago Would Be Worth Today
Via Benzinga
RPM International Posts Upbeat Earnings, Joins Joby Aviation, Ciena And Other Big Stocks Moving Higher On Wednesday
Via Benzinga

Performance

YTD
+170.58%
+170.58%
1 Month
+13.89%
+13.89%
3 Month
+12.85%
+12.85%
6 Month
+207.22%
+207.22%
1 Year
+78.61%
+78.61%

More News

Read More
Biotech Stocks : Are You A Trader Or A Longer Term Investor?
Via Talk Markets
Looking Into Novavax's Recent Short Interest
Via Benzinga
$1000 Invested In Novavax 5 Years Ago Would Be Worth This Much Today
Via Benzinga
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Via Benzinga
Exposures COVID-19
How Is The Market Feeling About Novavax?
Via Benzinga
Looking Into Novavax's Recent Short Interest
Via Benzinga
Should You Buy Novavax Stock After This Regulatory Win?
Via The Motley Fool
Why Are Novavax Shares Trading Lower Today?
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?
Via The Motley Fool
Exposures COVID-19
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
Via FinancialNewsMedia
Exposures COVID-19
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
FDA Approves Novavax's Updated COVID Vaccine Targeting Currently Circulating Variants
Via Benzinga
Exposures COVID-19 Product Safety
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
Via The Motley Fool
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
Via Benzinga
Exposures COVID-19 Product Safety
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Via Investor's Business Daily
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Via MarketBeat
Exposures COVID-19 Product Safety
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Via MarketBeat
Exposures COVID-19
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
Via Benzinga
Exposures COVID-19
NVAX Stock Earnings: Novavax Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.